Of the 18 approved OGNs on market, Aliri has supported 3 as they transitioned from preclinical to clinical to FDA approval.
Aliri is proud to be a trailblazer in the bioanalysis of RNAi therapeutics with significant experience supporting the development of oligonucleotides, which includes siRNAs, ASOs, PPMOs, ARCs/AOCs, and other RNAi conjugates.
Our tenured team of scientists are continuously innovating and adapting our methodologies for improved assay sensitivity and specificity to deliver accurate and reliable data to our sponsors.
This has led to the critical application and optimization of available analytical approaches, including novel SPE and hybridization extraction techniques.
For over 15 years, Aliri has supported the bioanalysis of oligonucleotides from early development through preclinical and Clinical Phases I-IV on the following platforms:
- LC-MS/MS
- LC/HRMS
- LC/FD
We offer service lines to cover plasma, urine, and all types of tissues, and are happy to provide upfront consultation on the best approach to achieve the most relevant results for your IND filing.
